Pink SheetThe most unusual aspect of the dozen applications with September 2023 goal dates at the US FDA is how unusual they aren’t. Standard reviews are the rule, even for the lone breakthrough therapy-designa
Pink SheetThe US FDA’s Center for Drug Evaluation and Research cleared two new molecular entities in the last days of September, both for rare diseases – intrahepatic cholangiocarcinoma for Taiho Pharmaceutica
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, Flagship Hope Combined Ef